The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > COMMENTARY
COMMENTARY
-
Chuikyo Moving toward Conclusion on Issue of Insurance Coverage for Heparinoid Drugs
January 15, 2018
-
Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls
December 28, 2017
-
Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform
November 8, 2017
-
With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
October 10, 2017
-
Epigenetic Drug Discovery Efforts Expanding, with Solid Cancers Now Being Targeted
September 1, 2017
-
MHLW Panel Elaborating Rules for Clinical Research Law, “Scholarship Donations” to Be a Major Focus
August 21, 2017
-
Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics
July 26, 2017
-
Did Voice of the Industry Reach Honebuto Policymakers?
June 21, 2017
-
As AG Momentum Continues, Mucosta AG to Hit Shelves 8 Years after Gx Entry
June 14, 2017
-
MHLW, MOF Agreed on CEFP Working Group Report, Continuation of Premium As-Is Seems Difficult
May 11, 2017
-
Will Government Take the Lead in Pricing Debate towards 2017 Fiscal Blueprint?
April 19, 2017
-
“Cash-and-Carry Dealers” and Their Peculiar Business Practices in the Spotlight in Wake of Counterfeit Harvoni Scandal
April 12, 2017
-
Is the Government’s 70% Interim Generic Share Target Achievable?
March 13, 2017
-
Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight
March 7, 2017
-
Will NHI Pricing Reform in Sluggish Domestic Market Trigger Industry Reorganization?
February 6, 2017
-
Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves
January 30, 2017
-
Hepatology Society Revises Hep C Treatment Guidelines; Looking to Future Research for Non-Responders to IFN-Free Treatment
December 14, 2016
-
Taltz Issue Exposes Forex-Sensitive Nature of Drug Pricing System
November 15, 2016
-
Are Biosimilars on Verge of Breakthrough in Japan? Initiatives Underway to Prepare for Full-Scale Entry of Major Biosimilars
October 25, 2016
-
Policymakers Face Balancing Act over Opdivo Re-Pricing
October 17, 2016
ページ
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…